UK markets closed

Esperion Therapeutics, Inc. (ESPR)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.6100-0.0200 (-0.76%)
At close: 04:00PM EST
2.6700 +0.06 (+2.30%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close2.6300
Bid2.6200 x 3200
Ask2.6200 x 3200
Day's range2.5000 - 2.6800
52-week range0.7000 - 6.7500
Avg. volume6,252,277
Market cap466.989M
Beta (5Y monthly)0.78
PE ratio (TTM)N/A
EPS (TTM)-2.2700
Earnings date27 Feb 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.54
  • GlobeNewswire

    Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    ANN ARBOR, Mich., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on February 13, 2024, the Company granted 66 new employees 204,900 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducemen

  • Insider Monkey

    Should You Sell Esperion Therapeutics (ESPR)?

    Tourlite Capital Management, an investment management firm, released its fourth quarter 2023 investor letter, a copy of which can be downloaded here. Tourlite Fund, LP Founder Class returned 1.1% for Q4 2023 and 8.8% for the year. Since its inception in April 2022, the fund returned 14.3% compared to 8.4%, and 0.5% returns for the S&P […]

  • Zacks

    Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

    Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.